EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses

Ying Huang iD, Shomoita Alam iD, Erica Andersen-Nissen, Lindsay N Carpp iD, One B Dintwe, Britta S Flach, Nicole Grunenberg, Fatima Laher iD, Stephen C De Rosa, Guido Ferrari iD, Craig Innes, Linda-Gail Bekker und 5 weitere

Viruses · 2024

DOI: 10.3390/v16091365 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Viruses, 2024. Verfasst von Ying Huang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Hauptthemen laut MEDLINE: AIDS Vaccines, HIV Infections, Immunoglobulin G, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Identifying correlations between immune responses elicited via HIV and non-HIV vaccines could aid the search for correlates of HIV protection and increase statistical power in HIV vaccine-efficacy trial designs. An exploratory objective of the HVTN 097 phase 1b trial was to assess whether immune responses [focusing on those supported as correlates of risk (CoR) of HIV acquisition] induced via the RV144 pox-prime HIV vaccine regimen correlated with those induced via tetanus toxoid (TT) and/or hepatitis B virus (HBV) vaccines. We measured TT-specific and HBV-specific IgG-binding antibody responses and TT-specific and HBV-specific CD4+ T-cell responses at multiple time points in HVTN 097 participants, and we assessed their correlations at peak time points with HIV vaccine (ALVAC-HIV and AIDSVAX B/E)-induced responses. Four correlations were significant [false discovery rate-adjusted p-value (FDR) ≤ 0.2]. Three of these four were with IgG-binding antibody responses to TT measured one month after TT receipt, with the strongest and most significant correlation [rho = 0.368 (95% CI: 0.096, 0.588; p = 0.008; FDR = 0.137)] being with IgG-binding antibody responses to MN gp120 gDneg (B protein boost) measured two weeks after the second ALVAC-HIV and AIDSVAX B/E boost. The fourth significant correlation [(rho = 0.361; 95% CI: 0.049, 0.609; p = 0.021; FDR = 0.137)] was between CD4+ T-cell responses to a hepatitis B surface antigen peptide pool, measured 2 weeks after the third HBV vaccination, and IgG-binding antibody responses to gp70BCaseAV1V2 (B V1V2 immune correlate), measured two weeks after the second ALVAC-HIV and AIDSVAX B/E boost. These moderate correlations imply that either vaccine, TT or HBV, could potentially provide a moderately useful immunogenicity predictor for the ALVAC-HIV and AIDSVAX B/E HIV vaccine regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AIDS VaccinesHIV InfectionsImmunoglobulin GCD4-Positive T-LymphocytesHumansMaleFemaleAdultTetanus ToxoidImmunogenicity, VaccineHIV AntibodiesHepatitis B VaccinesHIV-1Young AdultAntibodies, ViralViral Vaccines

Stichwörter der Autor:innen

HIV vaccineT-cell responsesbinding antibodiesbiomarkersimmune correlates

Substanzen

AIDS VaccinesImmunoglobulin GTetanus ToxoidAIDSVAX B-EHIV AntibodiesHepatitis B VaccinesALVAC vaccineAIDSVAXAntibodies, ViralViral Vaccines

Autor:innen und Institutionen

  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Department of Biostatistics, University of Washington, Seattle, WA 98195, USA.
  • Cape Town HVTN Immunology Laboratory, Cape Town 8001, South Africa.
  • Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Soweto, Johannesburg 2193, South Africa.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.

ORCID-Profile: Ying Huang, Shomoita Alam, Lindsay N Carpp, Fatima Laher, Guido Ferrari, James G Kublin, Peter B Gilbert

Förderung

  • NCI NIH HHS
  • National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH)
  • NIAID NIH HHS
  • National Cancer Institute of the NIH

Zitieren

APA

Huang, Y., Alam, S., Andersen-Nissen, E., Carpp, L. N., Dintwe, O. B., Flach, B. S., Grunenberg, N., Laher, F., De Rosa, S. C., Ferrari, G., Innes, C., Bekker, L. G., Kublin, J. G., McElrath, M. J., Tomaras, G. D., Gray, G. E., & Gilbert, P. B. (2024). Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses. Viruses. https://doi.org/10.3390/v16091365

Vancouver

Huang Y, Alam S, Andersen-Nissen E, Carpp LN, Dintwe OB, Flach BS, et al. Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses. Viruses. 2024. doi:10.3390/v16091365

BibTeX
@article{Huang2024,
  author = {Huang, Ying and Alam, Shomoita and Andersen-Nissen, Erica and Carpp, Lindsay N and Dintwe, One B and Flach, Britta S and Grunenberg, Nicole and Laher, Fatima and De Rosa, Stephen C and Ferrari, Guido and Innes, Craig and Bekker, Linda-Gail and Kublin, James G and McElrath, M Juliana and Tomaras, Georgia D and Gray, Glenda E and Gilbert, Peter B},
  title = {Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16091365}
}
Kostenlos starten →